Breaking
European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
🇪🇺 EMA

Mergers & Acquisitions

Page 1 • 1 item

Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
AnalysisPain managementMay 4, 2026

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era

Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to address its role in the opioid crisis. This landmark agreement aims to resolve thousands of lawsuits and redirect company assets towards addiction treatment and prevention.

Dr. Amina Farouk